NEW YORK — Harris & Harris Group, Inc. (NASDAQ:TINY), an investor in transformative companies enabled by disruptive science, is pleased to note that its portfolio company, TARA Biosystems, Inc., raised $2.25 million in a seed financing to build commercial operations in New York City. Harris & Harris Group led the financing with participation from the Partnership Fund for New York City and Alexandria Venture Investments. Based on research from the laboratories of Columbia University Professor Gordana Vunjak-Novakovic and University of Toronto Professor Milica Radisic, both scientific co-founders of TARA Biosystems, the company aims to capitalize on the need for more predictive technology for testing the safety and efficacy of new therapies and for the discovery of new drug compounds.

“TARA is a great example of our recent company building efforts. Harris & Harris Group co-founded the company with Professors Radisic and Vunjak-Novakovic, and Misti Ushio, our Chief Strategy Officer, is the founding CEO of TARA,” said Douglas Jamison, Chief Executive Officer of Harris & Harris Group. “We are a substantial investor in TARA, and TARA’s technology has applications in precision health and medicine, a market in which we are very actively involved.”

About Harris & Harris Group

Harris & Harris Group is a publicly traded venture capital firm that is also a business development company.